Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

Abstract

Background: Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein cholesterol (LDL-C) goals. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and atorvastatin (20 mg) in high-risk patients with hypercholesterolemia.

A comparative study of efficacy of atorvastatin, rosuvastatin, and atorvastatin + fibrates as lipid lowering agents

“…13 Michael et al showed reduction in HDL (40%) more in Atorvastatin and Fibrate combination than in Atorvastatin monotherapy. 12 This is similar to our result (3%, P <0.0001) in lowering HDL in Group I (Atorvatatin) vs Group III (Atorvastatin and Fibrate).…”

“…This is similar to Eliasson et al 11 Rosuvastatin 67%, Clearfield et al 12 (Rosuvastatin 10 mg reduced LDL-C levels significantly more than atorvastatin 20 mg at week 6 (44.6% vs. 42.7%, P <0.05). 11,12 In our result Atorvastatin with Fibrates was better than Atorvastatin monotherapy in decreasing LDL (34.66% vs 33.85%) our result was similar to the results of Karalis et al (33% vs 35%). 13 Michael et al showed reduction in HDL (40%) more in Atorvastatin and Fibrate combination than in Atorvastatin monotherapy.…”

Relationship Between Statin Type and Responsiveness to Clopidogrel in Patients Treated with Percutaneous Coronary Intervention: A Subgroup Analysis of the CILON-T Trial

“…More than 90% of the patients achieved their target LDL goal in both groups, which is higher than the rate reported in a previous report on patients with a different ethnic background 32) , perhaps because, in our study, the baseline LDL levels were not high and remained well controlled with conventional doses of both statins. We also confirmed that the administration of cilostazol therapy in addition to a statin had favorable effects on the HDL and triglyceride profiles, as suggested by previous studies 33,34) .…”

Atorvastatin — 20 Years in the Struggle for Life

“…С целью изучения липидмодулирующих возможностей последнего было выполнено большое количество исследований, пре-паратом сравнения в рамках которых достаточно часто выступал аторвастатин [7][8][9][10][11][12][13]. В большинстве подобных исследований розувастатин несколько пре-восходил аторвастатин во влиянии на уровень ХС-ЛПНП [7][8][9][10][11]. Однако в ряде исследований достовер-ных различий при сравнении отдельных доз аторва-статина и розувастатина не отмечалось.…”